In Situ Characterization of Intrahepatic Non-Parenchymal Cells in PSC Reveals Phenotypic Patterns Associated with Disease Severity

Liver-infiltrating T cells have been implicated in the pathogenesis of primary sclerosing cholangitis (PSC), however little information is available about changes in other cellular compartments in the liver during PSC. This study aimed to characterize non-parenchymal intrahepatic cells in PSC livers and to find associations between phenotypes and disease severity. Using immunohistochemistry, followed by automated image analysis and quantification and a principal component analysis, we have studied non-parenchymal intrahepatic cells in PSC-patient livers (n = 17) and controls (n = 17). We observed a significant increase of T cells in the PSC patients, localized to the fibrotic areas. MAIT cells, normally present at high numbers in the liver, were not increased to the same extent. PSC patients had lower expression of MHC class I than controls. However, the levels of NKp46+ NK cells were similar between patients and controls, nevertheless, NKp46 was identified as a phenotypic marker that distinguished PSC patients with mild from those with severe fibrosis. Beyond that, a group of PSC patients had lost expression of Caldesmon and this was associated with more extensive bile duct proliferation and higher numbers of T cells. Our data reveals phenotypic patterns in PSC patients associated with disease severity.

[1]  C. Loddenkemper,et al.  CD8 T cells primed in the gut‐associated lymphoid tissue induce immune‐mediated cholangitis in mice , 2014, Hepatology.

[2]  A. Santoni,et al.  The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells , 2014, Front. Immunol..

[3]  G. Gores,et al.  Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. , 2013, Gastroenterology.

[4]  M. Neurath,et al.  Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis , 2013, Hepatology.

[5]  Lieping Chen,et al.  Molecular mechanisms of T cell co-stimulation and co-inhibition , 2013, Nature Reviews Immunology.

[6]  A. Bertoletti,et al.  IL-7 Licenses Activation of Human Liver Intrasinusoidal Mucosal-Associated Invariant T Cells , 2013, The Journal of Immunology.

[7]  J. Nattermann,et al.  NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL- and NKG2D-dependent manner , 2012, Laboratory Investigation.

[8]  L. Fabris,et al.  Epithelial-mesenchymal interactions in biliary diseases. , 2011, Seminars in liver disease.

[9]  Christian Gieger,et al.  Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci , 2011, Nature Genetics.

[10]  A. Lohse,et al.  Immune tolerance: what is unique about the liver. , 2010, Journal of autoimmunity.

[11]  M. Sacks,et al.  Assessing the effects of transforming growth factor-beta1 on bladder smooth muscle cell phenotype. I. Modulation of in vitro contractility. , 2009, The Journal of urology.

[12]  E. Cholongitas,et al.  Pathogenesis of primary sclerosing cholangitis. , 2008, Journal of hepatology.

[13]  R. Chapman,et al.  Etiopathogenesis of primary sclerosing cholangitis. , 2008, World journal of gastroenterology.

[14]  S. Mohanan,et al.  Caldesmon is necessary for maintaining the actin and intermediate filaments in cultured bladder smooth muscle cells. , 2007, Cell motility and the cytoskeleton.

[15]  S. Kaneko,et al.  Effects of chenodeoxycholic and ursodeoxycholic acids on interferon-γ production by peripheral blood mononuclear cells from patients with primary biliary cirrhosis , 1995, Journal of Gastroenterology.

[16]  S. Curbishley,et al.  Hepatic Endothelial CCL25 Mediates the Recruitment of CCR9+ Gut-homing Lymphocytes to the Liver in Primary Sclerosing Cholangitis , 2004, The Journal of experimental medicine.

[17]  T. Starzl,et al.  T-lymphocyte subsets in liver tissues of patients with primary biliary cirrhosis (PBC), patients with primary sclerosing cholangitis (PSC), and normal controls , 1984, Journal of Clinical Immunology.

[18]  Ning Wang,et al.  Caldesmon-dependent switching between capillary endothelial cell growth and apoptosis through modulation of cell shape and contractility , 2004, Angiogenesis.

[19]  D. Adams,et al.  Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease , 2002, The Lancet.

[20]  D. Adams,et al.  MAdCAM‐1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM‐1 in chronic inflammatory liver disease) , 2001, Hepatology.

[21]  F. T. ten Kate,et al.  Immunohistochemical analysis of inflammation in primary sclerosing cholangitis , 1998, European journal of gastroenterology & hepatology.

[22]  D. V. van Thiel,et al.  Phenotypic and functional characteristics of lymphocytes isolated from liver biopsy specimens from patients with active liver disease , 1992, Hepatology.

[23]  Y. Calmus,et al.  Ursodeoxycholic acid (UDCA) in the treatment of chronic cholestatic diseases. , 1991, Biochimie.

[24]  F. Matsumura,et al.  Phosphorylation of non-muscle caldesmon by p34cdc2 kinase during mitosis , 1991, Nature.